TMCnet News

Australia Procedure Numbers for Gynecological Devices 2017 - Research and Markets
[May 17, 2017]

Australia Procedure Numbers for Gynecological Devices 2017 - Research and Markets


Research and Markets has announced the addition of the "Australia Procedure Numbers for Gynecological Devices 2017 - MedPro" report to their offering.

The greatest market limiter within the field of gynecology is the lack of drive towards office-based procedures and resulting decreased capital investment within gynecology. Despite robust clinical evidence that in-office procedures are safer, reduce patient cost, have higher physician reimbursement, convenient scheduling and improved patient satisfaction, there is still little incentive to move away from operating theaters or medical centers for diagnostic procedures such as hysteroscopy.

Investment in high-end endoscopy devices was a predominant trend in Australian gynecology in 2016. Despite the pressures of the economy and reductions to healthcare funding, the emphasis on superior optical quality with video capabilities is enabling the market value to increase for hysteroscopy. Hysteroscopy procedures are unique in Australia because physicians are using alternative endoscopes to perform a hysteroscopy procedure. The segmentation of both rigid and flexible endoscopes, as well as flexible endoscopes (laparoscoes and cystoscopes) and video endoscopes provide a complete overview of the capital equipment used to perform hysteroscopy procedures within the field of gynecology.



Australia is an anomaly in the sense that price sensitivity is not apparent in certain markets and so extreme in others that emerging technologies have a higher barrier to entry in Australia. Fluid management equipment and non-invasive laser technology are two emerging technologies that are fueling the market value of gynecological capital equipment globally. In Australia, however, fluid management equipment sales are minimal while laser technology has yet to erode competing markets. The forecasts provided within this report demonstrate the market changes expected to occur within the reporting period.

Key Topics Covered:


Executive Summary

1. Research Methodology

2. Disease Overview

3. Procedure Numbers

Companies Mentioned

  • Astec Bio
  • B-bridge International, Inc.
  • BTG
  • Boston Scientific
  • Carl Zeiss
  • Coloplast
  • Cook Medical
  • Cooper Surgical
  • Ecleris
  • Esco Global
  • FertiPro
  • Hologic
  • Hunter Scientific
  • Irvine Scientific
  • Johnson & Johnson
  • Karl Storz
  • Kitazato
  • Leica
  • Life Global
  • Medgyne
  • Medtronic
  • Merck KGaA - Genea Biomedx
  • Merit Medical Systems
  • Nidacon Medical
  • Olympus
  • Pentax (News - Alert)
  • Promis Medical
  • Reproline Medical
  • Richard Wolf
  • Rocket Medical
  • Stryker
  • Vitrolife
  • Vitromed

For more information about this report visit http://www.researchandmarkets.com/research/pvd45w/australia


[ Back To TMCnet.com's Homepage ]